Contemporary research on serotonergic psychedelic compounds has been rife with references to so-called 'mystical' subjective effects. Several psychometric assessments have been used to assess such effects, and clinical studies have found quantitative associations between 'mystical experiences' and positive mental health outcomes. The nascent study of psyched...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessDepression Improves Following Single Dose of PsilocybinNick ZagorskiNick ZagorskiPublished Online:26 Dec 2022https://doi.org/10.1176/appi.pn.2023.01.1.50AbstractPatients with treatment-resistant depression who receive a single dose of psilocybin may experience a reduction i...
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402-1411. doi:10.1056/ NEJMoa2032994
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offer Other BenefitsRichard KarelRichard KarelSearch for more papers by this authorPublished Online:23 May 2022https://doi.org/10.1176/appi.pn.2022.06.6.30AbstractA small study involving 24 participants found that psi...
Serotonin 2A receptor (5-HTR) agonist "classic psychedelics" are drawing increasing interest as potential mental health treatments. Recent work suggests psychedelics can exert persisting anxiolytic and antidepressant effects lasting up to several months after a single administration. Data indicate acute subjective drug effects as important psychological fact...
Depression is highly prevalent and represents the leading cause of global disability and primary contributor to overall global burden of disease. Several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large ...
BackgroundThe therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects.ObjectivesThis work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric dis...
Potent psychedelic drugs such as LSD and psilocybin are implicated in a multitude of cognitive and perceptual alterations. Through the mediation of serotonergic 5-HT2 receptors, distortion of the self is a common effect of these drugs. The self is usually referred to as an entity comprising physical and psychological attributes that are coherent within our s...
Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly o...
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects...
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open-label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with canc...
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is experiencing an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depr...
An exploration of personality predictor variables (absorption and temporal lobe lability) and acute experience measures (5D-ASC) in the comparison of several non-drug induced altered states (darkroom anechoic chamber, floatation tank and holotropic breathwork) with psychedelic altered states (e.g., DMT, psilocybin, cannabis).
Creative thinking and empathy are crucial for everyday interactions and subjective well-being. This is emphasized by studies showing a reduction in these skills in populations where social interaction and subjective well-being are significantly compromised (e.g., depression). Anecdotal reports and recent studies suggest that a single administration of psiloc...
Depression is one of the most disabling and prevalent mental disorders, which causes excessive feelings of sadness and despair. Unfortunately, there are a substantial number of patients that do not respond well to conventional interventions and new approaches are therefore needed. Recent studies have revealed that psilocybin can effectively reduce symptoms o...
Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometric database.